Literature DB >> 6951172

Relationship between the genetically determined acetylator phenotype and DNA damage induced by hydralazine and 2-aminofluorene in cultured rabbit hepatocytes.

C A McQueen, C J Maslansky, I B Glowinski, S B Crescenzi, W W Weber, G M Williams.   

Abstract

The relationship between acetylation rates of rabbit hepatocytes and their susceptibility to genotoxicity by DNA-damaging chemicals that undergo N-acetylation was studied in primary cultures of hepatocytes from New Zealand White rabbits that have a genetically determined difference in acetylation rates. Hepatocytes from rapid and slow acetylator rabbits maintained in culture the difference in acetylation rates that existed in vivo, DNA repair, an index of DNA damage, was produced by hydralazine in hepatocytes from slow acetylator rabbits but not in those from rapid acetylators. In contrast to these results, hepatocytes from rapid acetylators were more sensitive than those from slow acetylators to toxicity from the carcinogen 2-aminofluorene and displayed greater amounts of DNA repair. The amount of DNA repair measured with either chemical was dose dependent. These phenotype-dependent differences in the genotoxicity of two DNA-damaging chemicals provide evidence for the role of the acetylation polymorphism as a factor in determining susceptibility to toxicity, and perhaps carcinogenicity, of these chemicals.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6951172      PMCID: PMC345943          DOI: 10.1073/pnas.79.4.1269

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  41 in total

Review 1.  Late toxicity to hydralazine resembling systemic lupus erythematosus or rheumatoid arthritis.

Authors:  H M Perry
Journal:  Am J Med       Date:  1973-01       Impact factor: 4.965

2.  Procainamide-induced lupus erythematosus. Clinical and laboratory observations.

Authors:  S E Blomgren; J J Condemi; J H Vaughan
Journal:  Am J Med       Date:  1972-03       Impact factor: 4.965

3.  Immune responses to hydralazine and nuclear antigens in hydralazine-induced lupus erythematosus.

Authors:  B H Hahn; G C Sharp; W S Irvin; O S Kantor; C A Gardner; M K Bagby; H M Perry; C K Osterland
Journal:  Ann Intern Med       Date:  1972-03       Impact factor: 25.391

4.  Enzymatic N-acetylation of carcinogenic aromatic amines by liver cytosol of species displaying different organ susceptibilities.

Authors:  G M Lower; G T Bryan
Journal:  Biochem Pharmacol       Date:  1973-07-01       Impact factor: 5.858

5.  Polymorphic acetylation of drugs in rabbits.

Authors:  G R Gordon; A G Shafizadeh; J H Peters
Journal:  Xenobiotica       Date:  1973-03       Impact factor: 1.908

6.  Relationship of acetyl transferase activity to antinuclear antibodies and toxic symptoms in hypertensive patients treated with hydralazine.

Authors:  H M Perry; E M Tan; S Carmody; A Sakamoto
Journal:  J Lab Clin Med       Date:  1970-07

7.  N-hydroxy-2-fluorenylacetamide. Reaction of the carcinogen with guanosine, ribonucleic acid, deoxyribonucleic acid, and protein following enzymatic deacetylation or esterification.

Authors:  C M King; B Phillips
Journal:  J Biol Chem       Date:  1969-11-25       Impact factor: 5.157

8.  Enzyme-catalyzed reactions of the carcinogen N-hydroxy-2-fluorenylacetamide with nucleic acid.

Authors:  C M King; B Phillips
Journal:  Science       Date:  1968-03-22       Impact factor: 47.728

9.  The acetylator phenotype of patients with systemic lupus erythematosus.

Authors:  M M Reidenberg; J H Martin
Journal:  Drug Metab Dispos       Date:  1974 Jan-Feb       Impact factor: 3.922

10.  Multiple N-acetyltransferases and drug metabolism. Tissue distribution, characterization and significance of mammalian N-acetyltransferase.

Authors:  D J Hearse; W W Weber
Journal:  Biochem J       Date:  1973-03       Impact factor: 3.857

View more
  8 in total

1.  The hepatocyte primary culture/DNA repair test using hepatocytes from several species.

Authors:  C A McQueen; G M Williams
Journal:  Cell Biol Toxicol       Date:  1987-06       Impact factor: 6.691

2.  Effect of intra-articular glucocorticoids on the disposition of sulphadimidine in chronic osteoarthritis patients.

Authors:  P T Reeves; P Hanrahan; J Edelman; K F Ilett
Journal:  Br J Clin Pharmacol       Date:  1988-11       Impact factor: 4.335

3.  Role of Human N-Acetyltransferase 2 Genetic Polymorphism on Aromatic Amine Carcinogen-Induced DNA Damage and Mutagenicity in a Chinese Hamster Ovary Cell Mutation Assay.

Authors:  Kristin J Baldauf; Raúl A Salazar-González; Mark A Doll; William M Pierce; J Christopher States; David W Hein
Journal:  Environ Mol Mutagen       Date:  2019-09-30       Impact factor: 3.216

4.  Differences between human slow N-acetyltransferase 2 alleles in levels of 4-aminobiphenyl-induced DNA adducts and mutations.

Authors:  Jean Bendaly; Mark A Doll; Lori M Millner; Kristin J Metry; Ned B Smith; William M Pierce; David W Hein
Journal:  Mutat Res       Date:  2009-08-12       Impact factor: 2.433

5.  Berberine inhibited arylamine N-acetyltransferase activity and gene expression and DNA adduct formation in human malignant astrocytoma (G9T/VGH) and brain glioblastoma multiforms (GBM 8401) cells.

Authors:  D Y Wang; C C Yeh; J H Lee; C F Hung; J G Chung
Journal:  Neurochem Res       Date:  2002-09       Impact factor: 3.996

6.  Primary cultures and the levels of cytochrome P450 in hepatocytes from mouse, rat, hamster, and rabbit liver.

Authors:  C J Maslansky; G M Williams
Journal:  In Vitro       Date:  1982-08

7.  Modulation of genotoxic and cytotoxic effects of aromatic amines in monolayers of rat hepatocytes.

Authors:  J A Holme; E J Søderlund
Journal:  Cell Biol Toxicol       Date:  1984-10       Impact factor: 6.691

8.  Anti-neoplastic properties of hydralazine in prostate cancer.

Authors:  Inês Graça; Elsa J Sousa; Pedro Costa-Pinheiro; Filipa Q Vieira; Jorge Torres-Ferreira; Maria Gabriela Martins; Rui Henrique; Carmen Jerónimo
Journal:  Oncotarget       Date:  2014-08-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.